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Abstract: An accurate, sensitive and reproducible high performance liquid 
chromatographic (HPLC) method for the quantification of doxycycline hyclate 
in pharmaceutical samples has been developed and validated. The drug and the 
standard were eluted from a Lichrosorb RP-8 (250 mm×4.6 mm, 10 µm par-
ticle size) at 20 °C with a mobile phase consisting of methanol, acetonitrile and 
0.010 M aqueous solution of oxalic acid (2:3:5, v/v/v). The flow rate was 
1.25 ml min-1. A UV detector set at 350 nm was used to monitor the effluent. 
Each analysis required no longer than 4 min. The limits of detection and quan-
tification were 1.15 and 3.84 µg ml-1, respectively. Recoveries for different 
concentrations ranged from 99.58 to 101.93 %. 
Keywords: high performance liquid chromatography; doxycycline hyclate; ultra-
violet detection. 
INTRODUCTION 
Doxycycline (C22H24N2O8·H2O, molecular mass 462.5 g mol−1, CAS num-
ber: 17086-28-1), is the monohydrate of (4S,4aR,5S,5aR,6R,12aS)-4-(dimethyl-
amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11- 
-dioxonaphthacene-2-carboxamide, a substance obtained from oxytetracycline or 
metacycline or by other means.1 It is a broad spectrum anti-bacterial tetracycline 
derivative with a wide range of activity against gram positive and gram negative 
organisms, including Spirochetes, Actinomyces sp., and Mycoplasma sp.2 It is the 
drug of choice in the treatment of sexually transmitted diseases.3 Doxycycline is 
preferred to other tetracyclines in the treatment of specific infections because of 
its fairly reliable absorption and its long half-life, which permits less frequent 
dosage. Doxycycline hyclate (C22H24N2O8·HCl·0.5C2H5OH·0.5 H2O, molecular 
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mass 512.94 g mol−1, CAS number: 24390-14-5) is the hydrochloride 
hemiethanol hemihydrate of doxycycline. The synonym for doxycycline hyclate 
is doxycycline hydrochloride. Doxycycline hyclate is much more soluble than 
doxycycline monohydrate, which is one of the main reasons for it more frequent 
use in pharmaceutical samples. One of the broadly used and important veterinary 
pharmaceuticals is Tiadox powder. It is a complex powder with doxycycline hyc-
late as the main component. 
Various methods for determination of doxycycline in vitro and in vivo have 
been reported. These include microbiology,4 fluorimetry,5 TLC-fluorescence 
scanning densitometry6 and HPLC7−17 for the determination of doxycycline in 
biological materials. HPLC was also applied for the determination of doxycyc-
line in pharmaceutical formulations.18 Various chromatographic methods have 
also been reported for the determination of doxycycline in human tissues19 and 
foods.20,21 Derivative spectrophotometry (pharmaceuticals, urine and honey)22 
and sequential injection chromatography (SIC) methods (pharmaceutical prepara-
tions)23 for the determination of doxycycline have also been developed. Review-
ing literature data, it was concluded that there are a few methods reported for the 
determination of doxycycline hyclate in pharmaceutical samples (spectrophoto-
metric methods24−26 and HPLC methods27,28). The standard procedure is given 
in the British Pharmacopoeia.29 
HPLC offers several advantages over other techniques, including minimal 
sample manipulation before chromatography, rapid analysis and the simultaneous 
analysis of multiple compounds with good specificity, precision and accuracy. 
For this reason, a fast, simple method for the determination of doxycycline hyc-
late in the mentioned veterinary powder (Tiadox powder) was developed and is 
presented in this paper. The proposed method is reproducible, reliable and per-
mits more samples to be analyzed in a short period of time. 
EXPERIMENTAL 
Reagents and chemicals 
Doxycycline was obtained from PromoChem, Teddington, United Kingdom. All the em-
ployed solvents were of HPLC grade, while other chemicals were of spectroscopic grade and 
were obtained from Merck (Darmstadt, Germany). The Pharmaceutical Industry “Actavis”, 
Leskovac, supplied the Tiadox powder. It consists of various ingredients, among them doxy-
cycline hyclate (10.0 g doxycycline hyclate per 100 g of Tiadox powder) represents the only 
active component. 
HPLC apparatus and conditions 
The HPLC system consisted of an Agilent 1100 series isocratic LC system, an Agilent 
1100 series variable wavelength detector SL and a Hewlett Packard 1000 data system (Agilent 
Technologies, Inc., Santa Clara, CA, USA). The detector wavelength was set at 350 nm. The 
mobile phase consisted of methanol:acetonitrile:0.010 M oxalic acid (2:3:5, v/v/v). Routine 
degassing of the mobile phase was performed by passing it through a 0.45 µm membrane filter 
(Millipore, Bedford, MA, USA). The mobile phase was pumped isocratically at a flow rate of 
1.25 ml min-1 at 20 °C. The injection volume was 50 µl.   DETERMINATION OF DOXYCYCLINE HYCLATE  667 
 
Stock solutions 
Doxycycline hydrochloride (25 mg) was dissolved in 25 ml of mobile phase. The work-
ing solution was obtained by dilution of 1.0 ml of the stock solution to 10 ml with mobile phase. 
Assay procedure 
Tiadox powder (250 mg) was dissolved in 25 ml of mobile phase. This solution (1.0 ml) 
was diluted to 10 ml with mobile phase. 
RESULTS 
Assay validation 
A high performance liquid chromatographic method for the quantification of 
doxycycline hyclate concentrations in a pharmaceutical sample (Tiadox powder) 
was developed. The active ingredients were monitored by measurement of the 
peak area of both doxycycline hyclate from Tiadox powder and the standard, and 
the ratio of the peak areas was calculated. The specificity of the chromatographic 
method was determined by the screening of a placebo solution and the assay so-
lution. The placebo solution was prepared in the same manner as the investigated 
solution but without doxycycline hyclate. Typical chromatograms of the standard 
and assay solution are presented in Figs. 1 and 2, respectively. 
Fig.  1. Representative chroma-
togram of a standard solution of 
doxycycline hyclate. 
Linearity 
The linearity was checked on samples of standard doxycycline hydrochloride 
at five different concentrations (25.2–252.0 µg ml−1). 
A regression curve was constructed: 
 y  = 77498x − 72.455, with R2 = 0.9997 
where x represents concentration in µg ml−1, y represents the HPLC peak area, 
which was automatically measured by an integrator of the HPLC instrument, and 
R is the correlation coefficient. The calculations were performed on a personal 
computer using the Microsoft Excel program (Version 2003, Microsoft Co., Red-
mond, USA, 2003). 668 MITIĆ et al. 
 
Fig. 2. Representative chroma-
togram of an assay solution – 
– Tiadox powder. 
Accuracy 
The accuracy of the method was checked by determining recovery values. 
Series of solution were made containing 80, 100 and 120 % of doxycycline hyc-
late regarding the declared content. The results are presented in Table I. 
TABLE I. Accuracy of the method 
Concentration 
g/100g 
Recovery 
% 
N xsr  SD 
RSD 
% 
101.7 
101.4 
8.00 
101.4 
3 101.5  0.1819  0.1809 
101.8 
100.2 
10.00 
99.6 
3 100.5  1.108  1.102 
100.8 
101.9 
12.00 
101.9 
3 101.6  0.6264  0.6167 
Limit of detection and quantification 
The limit of detection (LOD) and quantification (LOQ) were calculated ac-
cording to the following formula: 
 LOD = 3Sdo/bsr = 1.15 µg ml−1 
 LOQ = 10Sdo/bsr = 3.84 µg ml−1 
where Sdo is the standard deviation of the response and bsr is the mean value of 
the slope of the calibration curve constructed during the linearity determination. 
Precision 
The precision was determined by measuring five sample probes under the 
same experimental conditions. The obtained results are given in Table II, to-
gether with the calculated values of their standard deviation, SD, and relative 
standard deviation, RSD.   DETERMINATION OF DOXYCYCLINE HYCLATE  669 
 
TABLE II. Precision of the method 
N 
Content of doxycycline hyclate in 
Tiadox powder, g/100g 
xsr  SD 
RSD 
% 
9.98 
9.71 
9.81 
9.78 
5 
9.82 
9.82 0.0992  1.01 
The method is precise since RSD < RSDmax. RSDmax is 2 %, which repre-
sents the maximum allowed value of the RSD for HPLC methods according to 
the Pharmacopoeias. 
DISCUSSION 
A comparison of the proposed method with other methods is given in Table 
III. The results obtained by the proposed method have an RSD of 1.01 %, better 
than that reported by Šatínský et al.22, Salinas et al.23 and Lopez-Paz and Mar-
tinez Calatayud.24 The first two methods22,23 have relatively high RSD values, 
higher than RSDmax. This suggests that the proposed method is more precise than 
some of the previously published methods. The LOD values22,23 were also a little 
higher than in the method described in this paper. Mahrous and Abdel-Khalek25 
described a long pre-treatment of the drug through mixing with acetic acid and 
sodium cobalt nitrite, then boiling the mixture, followed by cooling. In addition, 
the same author26 described a determination employing ammonium vanadate. On 
the other hand, Hoogmartens et al.27 revealed a method for the determination of 
doxycycline hyclate by HPLC using poly(styrene–divinylbenzene) packing mate-
rials. Estimates for the repeatability and reproducibility of the method, expressed 
as relative standard deviations of the results of the determination of doxycycline 
hyclate, were found to be 0.90 and 1.20 %, respectively. The authors27 used a 
complex mobile phase, consisting of 2-methyl-2-propanol, 0.2 M potassium hyd-
rogen phosphate buffer, tetrabutylammonium hydrogen sulfate and 0.10 M 
Na2EDTA. Using this mobile phase system, the analysis time is about 20 min, 
which is 5 times longer, compared to the method proposed in this paper. 
TABLE III. Comparison of the proposed method with other methods for the determination of 
doxycycline hyclate in pharmaceutical preparations 
Ref.  
Concentration 
range, µg ml-1 
RSDa 
% 
Recovery 
% 
LOD 
µg ml-1 
Comments, conditions 
This 
paper  25.20–252.00  1.01  100.2  1.15  HPLC, UV detection
 
22 2.00–100.00  5.05  99.3 
102.8 
2.00 Sequential  injection 
chromatography
 
23  − 0.78–5.00b 95 0.6-3.00b  Derivative spectrophotometry 
24  10.00–80.00 1.40d  2.3c  − FIA-spectrophotometry 670 MITIĆ et al. 
 
Table III. Continued 
Ref.  
Concentration 
range, µg ml-1 
RSDa 
% 
Recovery 
% 
LOD 
µg ml-1 
Comments, conditions 
25 10.00–30.00  − 100.3  − Spectrophotometry 
26 20.00–100.00  − 99.6  − Spectrophotometry 
28  − 0.1–1.7e 92–107e  −  HPLC, UV detection  
aRSD values were taken and compared for concentrations of ≈ 10 µg ml-1 of doxycycline; branges of RSD and 
LOD values at different first-derivative signals; crelative error; dRSD for samples containing 2.5 µg ml-1 of 
doxycycline; erecovery range for different pharmaceuticals 
CONCLUSION 
The proposed HPLC method provides a rapid, sensitive, accurate, and repro-
ducible determination of doxycycline hyclate in pharmaceutical samples, without 
sample derivatization. 
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ИЗВОД 
БРЗО И ПОУЗДАНО ОДРЕЂИВАЊЕ ДОКСИЦИКЛИН-ХИКЛАТА МЕТОДОМ HPLC 
СА UV ДЕТЕКЦИЈОМ У ФАРМАЦЕУТСКИМ УЗОРЦИМА 
СНЕЖАНА С. МИТИЋ1, ГОРДАНА Ж. МИЛЕТИЋ1, ДАНИЈЕЛА А. КОСТИЋ1, ДАНИЕЛА Ч. НАСКОВИЋ-
ЂОКИЋ2, БИЉАНА Б. АРСИЋ1 И ИВАНА Д. РАШИЋ1 
1Odsek za hemiju, Prirodno–matemati~ki fakultet, Vi{egradska 33, 18000 Ni{ i 
2D. D. “Zdravqe–Aktavis” – Farmaceutska i hemijska kompanija, 16000 Leskovac 
Тачна, осетљива и репродуктивна метода високо ефективне течне хроматографије (HPLC) 
за квантификацију доксициклин-хиклата у фармацеутским узорцима је развијена и потвр-
ђена. Лек и стандард су елуирани са колоне Lichrosorb RP-8 (250 mm×4,6 mm, величине чес-
тицe од 10 µm) на 20 ºC са мобилном фазом која се састојала од метанола, ацетонитрила и 
0,010 М воденог раствора оксалне киселине (2:3:5, v/v/v). Брзина протока је била 1,25 ml min-1. 
За праћење ефлуента коришћен је UV детектор подешен на 350 nm. Свака анализа је трајала 
не дуже од 4 минута. Граница детекције је 1,15, док је граница квантификације 3,84 µg ml-1. 
Ефикасност за различите концентрације се креће од 99,6 до 101,9 %. 
(Примљено 14. септембра, ревидирано 7. новембра 2007) 
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